December 10, 2019Journal of Clinical OncologyOpen Access

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

View Full Paper

Ask AI

Bookmark

Abstract

The addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2-overexpressing IBC. Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fehrenbacher et al. (2019) studied this question.

synapsesocial.com/papers/69df3fa56324afb55d591ca3 https://doi.org/10.1200/jco.19.01455

View Full Paper

Ask AI

Bookmark

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Abstract

Discussion

Cite This Study

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Abstract

Discussion

Cite This Study

Also Consider

Also Consider